概括
手术后的短期甲化疗显著提高了结直肠癌患者的生存率. 这种辅助疗法在第三阶段的疾病中增加了5年生存率33.2%,在第二阶段的疾病中增加了23.1%.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 医学瘤学 医学瘤学
背景情况:
- 结肠直肠癌的治疗通常需要手术.
- 辅助化疗可能会改善手术后的结果.
- 甲是一种常见的化疗剂.
研究的目的:
- 评估结直肠癌治愈性手术后短期甲化学预防的有效性.
- 评估甲对II期和III期结直肠癌的生存率的影响.
主要方法:
- 研究了一组同质的213名结直肠癌患者.
- 患者要么单独接受手术,要么接受手术后进行短期的甲化学预防疗法.
- 五年和更短的生存率 (没有疾病的证据) 被组对组进行了比较.
主要成果:
- 在第三阶段 (杜克斯C) 疾病中,使用甲 (P<.01) 的五年生存率从24.3%增加到57.5%.
- 在II阶段 (杜克斯B) 疾病中,使用甲 (P<.02) 的五年生存率从58.5%增加到81.6%.
- 在II和III阶段的整体5年生存率增加了28.1% (P<.01) 随着甲化学预防.
结论:
- 短期甲化学预防显著改善了II期和III期结直肠癌患者的五年治愈率.
- 辅助甲治疗对这些患者群体的手术治疗来说是一个有价值的补充.
更多相关视频
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...